REFRACTORY CANCER

This study tests whether adding omeprazole (a common heartburn drug) to chemotherapy (cabazitaxel or docetaxel) can help control advanced prostate cancer that has stopped responding to standard treatments. About 50 men with castration-resistant prostate cancer that progressed aft…

This early-phase trial tests an experimental drug called IMA402 in about 145 adults with solid tumors that have returned or not responded to standard treatments. The drug is designed to help the immune system find and attack cancer cells that carry a protein called PRAME. The mai…

This study tests whether teclistamab, a drug for relapsed/refractory multiple myeloma, can be given safely in an outpatient setting instead of requiring a hospital stay. It involves 15 patients who have already tried at least three other treatments. The goal is to reduce hospital…

This early-stage study tests a new treatment called MQ710, made from a modified virus, for people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors, either alone or with the immunotherapy drug pembrolizumab. T…

This study tests new cancer drugs that are chosen based on the unique genetic makeup of each child's tumor. It is for children, teens, and young adults with advanced solid tumors, brain tumors, or lymphomas that have not responded to standard treatments. The goal is to find the r…

This study tests a new treatment for adults with solid tumors that have come back or not responded to standard therapies. The treatment uses a patient's own immune cells that are genetically modified to recognize and attack cancer cells. Some participants will also receive the dr…

This study tests a combination of two drugs, zanubrutinib and pemetrexed, in people whose central nervous system lymphoma has returned or not responded to prior treatment. The goal is to see if this approach can shrink tumors and control the disease. About 15 participants will re…

This study tests a combination of three drugs (pembrolizumab, ibrutinib, and rituximab) in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if the combo can control the cancer for at least 6 months. About 3…

This study tests a new treatment called iC9.CAR-CSPG4 T cells for people with head and neck cancer that has returned after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals ar…

This early-phase study tests a new drug called ADU-1805, alone or with another cancer drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the drug moves through the body. About 130 p…

This study tests a new drug called BGB-16673, which breaks down a protein that helps cancer cells grow, combined with other treatments. It is for people with B-cell blood cancers (like lymphoma) that have returned or not responded to prior therapy. The goal is to find safe doses …

This study tests a new treatment called 177Lu-SN201 for people with advanced solid tumors that have not responded to standard therapies. The treatment uses tiny particles that deliver radiation directly to tumors. The goal is to find the safest dose and see if it can shrink tumor…

This study tests a new drug, epcoritamab, combined with standard chemotherapy (GDP) in 32 adults whose large B-cell lymphoma has returned or not responded to treatment. The goal is to see if this combination can shrink or eliminate the cancer. After three cycles, patients may pro…

This early-phase study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with solid tumors that have returned or not responded to treatment. The main goal is to find a safe dose with manageable side effects. The drugs targe…